

Kerstin Wa Westman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3799118/publications.pdf>

Version: 2024-02-01

45
papers

7,325
citations

172386

29
h-index

233338

45
g-index

46
all docs

46
docs citations

46
times ranked

3861
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 211-220.	13.9	1,471
2	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. <i>New England Journal of Medicine</i> , 2003, 349, 36-44.	13.9	1,239
3	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2009, 150, 670.	2.0	790
4	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 488-494.	0.5	719
5	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.5	348
6	Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 542-548.	6.7	298
7	Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. <i>Kidney International</i> , 2013, 84, 397-402.	2.6	220
8	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1178-1182.	0.5	217
9	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.5	214
10	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1003-1010.	0.5	183
11	Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. <i>Kidney International</i> , 1999, 56, 1544-1550.	2.6	152
12	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	1.5	147
13	Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3472-3477.	6.7	117
14	Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. <i>British Journal of Rheumatology</i> , 2003, 43, 174-180.	2.5	107
15	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	0.9	104
16	Development of comprehensive disease assessment in systemic vasculitis. <i>Postgraduate Medical Journal</i> , 2008, 84, 143-152.	0.9	91
17	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , 2011, 50, 899-905.	0.9	89
18	Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan. <i>Journal of Rheumatology</i> , 2014, 41, 325-333.	1.0	83

#	ARTICLE	IF	CITATIONS
19	Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody: Technical Note. <i>Kidney International</i> , 1998, 53, 1230-1236.	2.6	82
20	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1128-1135.	2.2	75
21	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1571-1576.	2.2	53
22	Neutrophil-Derived Proteinase 3 Induces Kallikrein-Independent Release of a Novel Vasoactive Kinin. <i>Journal of Immunology</i> , 2009, 182, 7906-7915.	0.4	50
23	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.5	47
24	Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1468-1475.	1.0	47
25	A Novel C3 Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical Hemolytic Uremic Syndrome. <i>Journal of Immunology</i> , 2012, 188, 2030-2037.	0.4	46
26	Declining Estimated Glomerular Filtration Rate and Its Association with Mortality and Comorbidity Over 10 Years in Elderly Women. <i>Nephron</i> , 2015, 130, 245-255.	0.9	45
27	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , 2017, 19, 129.	1.6	42
28	Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis. <i>RMD Open</i> , 2017, 3, e000435.	1.8	33
29	Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. <i>Rheumatology</i> , 2017, 56, 1894-1901.	0.9	31
30	The long-term outcomes of systemic vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i60-6.	0.4	29
31	Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. <i>Rheumatology</i> , 2017, 56, kew465.	0.9	24
32	Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2020, 47, 1229-1237.	1.0	22
33	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.4	21
34	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.	0.4	21
35	Living Anonymous Renal Donors Do Not Regret: Intermediate and Long-Term Follow-Up with a Focus on Motives and Psychosocial Outcomes. <i>Annals of Transplantation</i> , 2019, 24, 234-241.	0.5	17
36	Low individualized growth hormone (GH) dose increased renal and cardiac growth in young adults with childhood onset GH deficiency. <i>Clinical Endocrinology</i> , 2001, 55, 741-748.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Dialysis-linked complaints and burdens of illness on patient and spouse as predictors of survival in end-stage renal disease patients with home hemodialysis: a 10-year follow-up study. <i>Stress and Health</i> , 2004, 20, 29-34.	1.4	8
38	Persistent High Prevalence of Thyroid Antibodies after Immunosuppressive Therapy in Subjects with Glomerulonephritis. <i>American Journal of Nephrology</i> , 1998, 18, 274-279.	1.4	7
39	Elevated Plasma Levels of Acute Phase Proteins in Mesangioproliferative Glomerulonephritis, Membranous Nephropathy and IGA Nephropathy. <i>Scandinavian Journal of Urology and Nephrology</i> , 1995, 29, 5-9.	1.4	5
40	DEMONSTRATION AND CLASSIFICATION OF AMYLOIDOSIS IN NEEDLE BIOPSIES OF THE KIDNEYS, WITH SPECIAL REFERENCE TO AMYLOIDOSIS OF THE AA-TYPE. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology</i> , 1987, 95A, 357-363.	0.3	5
41	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2020, 47, 580-588.	1.0	5
42	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. <i>Kidney International Reports</i> , 2022, 7, 1745-1757.	0.4	3
43	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 844-844.	6.7	1
44	Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis. <i>European Journal of Rheumatology</i> , 2018, 5, 153-159.	1.3	1
45	FC058: Long-Term Renal Survival of Anca-Associated Vasculitis Patients Included in the Euvas Randomized Clinical Trials. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	1